<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753840</url>
  </required_header>
  <id_info>
    <org_study_id>HenanICE202103</org_study_id>
    <nct_id>NCT04753840</nct_id>
  </id_info>
  <brief_title>Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension</brief_title>
  <official_title>Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Institute of Cardiovascular Epidemiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Institute of Cardiovascular Epidemiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the latest survey data of China hypertension annual meeting, there are about 300&#xD;
      million patients with hypertension in China, with 10 million new cases of hypertension each&#xD;
      year, and there is an obvious trend of younger people. In particular, young and middle-aged&#xD;
      people are in a state of mild hypertension for a long time, which causes great pressure on&#xD;
      health and medical treatment. At present, the main clinical measures for mild hypertension&#xD;
      are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle&#xD;
      changes, as well as drug control. For most patients with mild hypertension, drug control is&#xD;
      not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may&#xD;
      play an effective role in reducing blood pressure .The purpose of this study was to&#xD;
      investigate the extent of long-term application of RIPC to reduce blood pressure in patients&#xD;
      with mild hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 200 patients with mild hypertension were enrolled in this study, using the method&#xD;
      of open label and parallel grouping; 100 cases in the experimental group and 100 cases in the&#xD;
      control group, The experimental group was divided into life intervention + drug group and&#xD;
      life intervention + ripc group, with 50 patients in each group. The results of 24-hour&#xD;
      ambulatory blood pressure monitoring (ABPM) of the three groups were observed before and 3&#xD;
      months after use, including HR, pulse pressure, 24-hour systolic blood pressure, 24-hour&#xD;
      diastolic blood pressure, daytime systolic blood pressure, daytime diastolic blood pressure,&#xD;
      nighttime systolic blood pressure and nighttime diastolic blood pressure. The changes of&#xD;
      renalase, catecholamine, renin, angiotensin - Ⅱ, aldosterone, RhoA kinase, no, adenosine and&#xD;
      bradykinin were observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>24-hour Mean systolic blood pressure measured by Ambulatory blood pressure monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean diastolic blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>24-hour Mean diastolic blood pressure measured by Ambulatory blood pressure monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Renalase</measure>
    <time_frame>3 months</time_frame>
    <description>blood renalase concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of catecholamine</measure>
    <time_frame>3 months</time_frame>
    <description>Blood catecholamine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of adenosine</measure>
    <time_frame>3 months</time_frame>
    <description>blood adenosine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of bradykinin</measure>
    <time_frame>3 months</time_frame>
    <description>blood bradykinin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of renin</measure>
    <time_frame>3 months</time_frame>
    <description>blood renin concentration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Experimental A: Drug group+lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group A used only one antihypertensive drug (ACEI / ARB, beta blocker, calcium channel blocker, diuretic, etc.) plus lifestyle intervention to control blood pressure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental B: RIPC group+lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group B received ripc treatment of upper limbs every day plus lifestyle intervention until the end of the follow-up. The treatment time was 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental c: lifestyle intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group take lifestyle intervention to control blood pressure, such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antihypertensive drugs</intervention_name>
    <description>One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic</description>
    <arm_group_label>Experimental A: Drug group+lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>remote ischemic preconditioning（RIPC）</intervention_name>
    <description>40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.</description>
    <arm_group_label>Experimental B: RIPC group+lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle intervention</intervention_name>
    <description>Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.</description>
    <arm_group_label>Experimental A: Drug group+lifestyle intervention</arm_group_label>
    <arm_group_label>Experimental B: RIPC group+lifestyle intervention</arm_group_label>
    <arm_group_label>Experimental c: lifestyle intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed patients with mild hypertension (SBP: 140~159mmHg; DBP: 90~99mmHg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cannot tolerate RIPC&#xD;
&#xD;
          -  Non-essential hypertension&#xD;
&#xD;
          -  patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance&#xD;
&#xD;
          -  patients who have severe organic diseases such acute myocardial infarction, cardiac&#xD;
             insufficiency, abnormal renal function, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muwei Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Central China Cardiovascular Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>En Li</last_name>
    <phone>13525070525</phone>
    <email>1799077212@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai central China Cardiovascular hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muwei Li, MD</last_name>
      <phone>+8613838083966</phone>
      <email>lmw0207@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens. 2014 Jul;27(7):918-25. doi: 10.1093/ajh/hpu004. Epub 2014 Mar 13.</citation>
    <PMID>24627443</PMID>
  </reference>
  <reference>
    <citation>Moro L, Pedone C, Mondì A, Nunziata E, Antonelli Incalzi R. Effect of local and remote ischemic preconditioning on endothelial function in young people and healthy or hypertensive elderly people. Atherosclerosis. 2011 Dec;219(2):750-2. doi: 10.1016/j.atherosclerosis.2011.08.046. Epub 2011 Sep 7.</citation>
    <PMID>21945497</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD can be obtained from the researcher upon reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

